Literature DB >> 20800911

Activation of matrix metalloproteinase-9 is associated with mobilization of bone marrow-derived cells after coronary stent implantation.

Teruo Inoue1, Isao Taguchi, Shichiro Abe, Shigeru Toyoda, Kohsuke Nakajima, Masashi Sakuma, Koichi Node.   

Abstract

BACKGROUND: After stent-related vascular injury, an inflammatory response triggers the mobilization of bone marrow-derived stem cells, including both endothelial and smooth muscle progenitors, leading to re-endothelialization as well as restenosis. It has been postulated that neutrophil-released matrix metalloproteinase-9 (MMP-9) induces stem cell mobilization. AIM: To elucidate the mechanistic link between inflammation and stem cell mobilization after coronary stenting.
METHODS: In 31 patients undergoing coronary stenting, we serially measured activated Mac-1 on the surface of neutrophils and active MMP-9 levels in the coronary sinus blood plasma, and the number of circulating CD34-positive cells in the peripheral blood.
RESULTS: After bare-metal stent implantation (n=21), significant increases in the numbers of CD34-positive cells (maximum on post-procedure day 7, P<0.001), activated Mac-1 (at 48 h, P<0.001), and active MMP-9 levels (at 24h, P<0.001) were observed. However, these changes were absent after sirolimus-eluting stent implantation (n=10). In overall patients, the numbers of CD34-positive cells on day 7 (R=0.58, P<0.01) and activated Mac-1 at 48 h (R=0.58, P<0.01) were both correlated with active MMP-9 levels at 24h. Stimulation of activated Mac-1 on the surface of isolated human neutrophils produced active MMP-9 release in vitro.
CONCLUSIONS: These results suggest that stent-induced activation of Mac-1 on the surface of neutrophils might trigger their MMP-9 release, possibly leading to the mobilization of bone marrow-derived stem cells. These reactions were substantially inhibited by sirolimus-eluting stents.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800911     DOI: 10.1016/j.ijcard.2010.07.028

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation.

Authors:  Yuji Naito; Misty Williams-Fritze; Daniel R Duncan; Spencer N Church; Narutoshi Hibino; Joseph A Madri; Jay D Humphrey; Toshiharu Shinoka; Christopher K Breuer
Journal:  Cells Tissues Organs       Date:  2011-10-12       Impact factor: 2.481

2.  Soluble CD40 ligand stimulates the pro-angiogenic function of peripheral blood angiogenic outgrowth cells via increased release of matrix metalloproteinase-9.

Authors:  Lara Bou Khzam; Rahma Boulahya; Haissam Abou-Saleh; Ahmed Hachem; Younes Zaid; Yahye Merhi
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

Review 3.  Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.

Authors:  Qishan Chen; Min Jin; Feng Yang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Mediators Inflamm       Date:  2013-06-12       Impact factor: 4.711

4.  Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Authors:  Antonietta Rosella Farina; Andrew Reay Mackay
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

5.  Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography.

Authors:  Masashi Sakuma; Takahisa Nasuno; Shichiro Abe; Syotaro Obi; Shigeru Toyoda; Isao Taguchi; Ryoichi Sohma; Ken-Ichi Inoue; Setsu Nishino; Koichi Node; Guiherme Attizzani; Hiram Bezerra; Marco Costa; Daniel Simon; Teruo Inoue
Journal:  Int J Cardiol Heart Vasc       Date:  2018-02-16

6.  Drug-Eluting Stent Targeting Sp-1-Attenuated Restenosis by Engaging YAP-Mediated Vascular Smooth Muscle Cell Phenotypic Modulation.

Authors:  Chen Huang; Jie Zhao; Yuelin Zhu
Journal:  J Am Heart Assoc       Date:  2019-12-27       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.